Outlook Therapeutics Management

Management criteria checks 2/4

Outlook Therapeutics' El consejero delegado es Russ Trenary , nombrado en Jul 2021, tiene un mandato de 2.58 años. la remuneración anual total es $1.76M , compuesta por 34.1% salario y 65.9% primas, incluidas acciones y opciones de la empresa. posee directamente 1.21% de las acciones de la empresa, por valor de €1.26M . La antigüedad media del equipo directivo y del consejo de administración es de 2.3 años y 4.7 años respectivamente.

Key information

Russ Trenary

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage	34.1%
CEO tenure	2.8yrs
CEO ownership	0.7%
Management average tenure	2.5yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Russ Trenary's remuneration changed compared to Outlook Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	US$2m	US$600k	-US$59m
Jun 30 2023	n/a	n/a	-US$60m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	n/a	n/a	-US$70m
Sep 30 2022	US$1m	US$600k	-US$66m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$60m
Dec 31 2021	n/a	n/a	-US$53m
Sep 30 2021	US$8m	US$145k	-US$53m

Compensación vs. Mercado: Russ($USD1.76M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD414.42K).

Compensación vs. Ingresos: La compensación de Russ ha aumentado mientras la empresa no es rentable.

CEO

Russ Trenary (65 yo)

2.8yrs

Tenure

US$1,758,862

Compensation

Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% $ 5.1k
C. Trenary	President	2.8yrs	US$1.76m	0.73% $ 1.3m
Lawrence Kenyon	Executive VP	8.6yrs	no data	0.0044% $ 8.1k
Jeffrey Evanson	Chief Commercial Officer	5.4yrs	US$718.20k	0.19% $ 345.4k
Alicia Tozier	Senior Vice President	2.1yrs	no data	no data
Joel Prieve	Senior Vice President of Licensing and M&A	2.2yrs	no data	no data
Surendra Sharma	Senior Vice President of Medical Affairs	1.3yrs	no data	no data
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	no data	no data
Jedd Comiskey	Senior VP - Head of Europe	less than a year	no data	no data

2.5yrs

Average Tenure

61yo

Average Age

Equipo directivo experimentado: 41ONEl equipo directivo de la empresa se considera experimentado (2.3 años de antigüedad media).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% $ 5.1k
C. Trenary	President	2.8yrs	US$1.76m	0.73% $ 1.3m
Lawrence Kenyon	Executive VP	5.7yrs	no data	0.0044% $ 8.1k
Kurt Hilzinger	Independent Director	8.3yrs	US$95.00k	0.11% $ 202.1k
Julia Haller	Independent Director	1.7yrs	US$79.00k	0% $ 0
Julian Gangolli	Independent Non-Employee Director	4yrs	US$112.50k	0% $ 0
Arun Pillai	Board Observer	no data	no data	no data
Gerd Auffarth	Independent Non-Employee Director	4yrs	US$79.00k	0% $ 0
Faisal Sukhtian	Independent Director	6.6yrs	US$113.00k	0.016% $ 29.0k
Yezan Haddadin	Independent Director	6.5yrs	US$110.00k	0.023% $ 43.1k
Andong Huang	Independent Director	3.8yrs	US$75.00k	0% $ 0

4.8yrs

Average Tenure

62yo

Average Age

Junta con experiencia: La junta directiva de 41ON se considera experimentada (4.5 años de antigüedad promedio).

Outlook Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

High number of new directors

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

High number of new directors

Chief Commercial Officer recently sold €189k worth of stock

Recent updates

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

New major risk - Shareholder dilution

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Forecast breakeven date moved forward to 2024

High number of new directors

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

High number of new directors

Chief Commercial Officer recently sold €189k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought €112k worth of stock

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought €227k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Forecast to breakeven in 2024

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Forecast to breakeven in 2023

Outlook Therapeutics, Inc. Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics, Inc. Provides Update on the Clinical Progress of ONS-5010 (Bevacizumab-Vikg) in Virtual Clinical Day

Outlook Therapeutics, Inc., Annual General Meeting, Mar 24, 2021

Chief Operating Officer recently sold €134k worth of stock

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Recent Financing Secures Funding to Support Ons-5010 / Lytenava™ Through Planne Bla Submission

New 90-day high: €1.50

New 90-day high: €1.08

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New 90-day high: €1.07

Outlook Therapeutics, Inc. Announces Board Appointments

Outlook Therapeutics, Inc. announced that it has received $10 million in funding

Outlook Therapeutics, Inc. Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-Vikg for Advanced Macular Degeneration

New 90-day low - €0.50

New 90-day low - €0.58

Earnings released

Outlook Therapeutics, Inc. announced that it has received $1 million in funding from Syntone Ventures LLC

CEO Compensation Analysis

CEO